8-K: BIOLASE, Inc. Enters Forbearance Agreement Amidst Default and Delisting

BIOLASE, Inc. has entered into a forbearance agreement with its lenders to avoid immediate loan acceleration and to facilitate a sale of assets through a Chapter 11 bankruptcy filing.

Summary

• BIOLASE, Inc. received a default notice from its lenders due to missed payments under a credit agreement.
• To avoid immediate enforcement actions, BIOLASE entered into a forbearance agreement with its lenders on August 31, 2024.
• The forbearance agreement prevents lenders from accelerating loan payments or exercising default remedies during the forbearance period.
• The forbearance period ends on the earlier of a forbearance default or October 7, 2024.
• The agreement includes a commitment for up to $2.5 million in bridge loans to cover operating expenses.
• BIOLASE is required to prepare for and file a Chapter 11 bankruptcy case for the sale of its assets.
• The company must enter into a purchase agreement with a stalking horse bidder by September 30, 2024, file for bankruptcy by October 1, 2024, and close the sale by November 15, 2024.
• The company's stock was delisted from Nasdaq and is now trading on the OTCQB Venture Market.
• The agreement also amends the credit agreement to reduce the minimum required consolidated unencumbered liquid assets to $1,000,000 after December 31, 2023, down from $2,500,000.

Sentiment

Score: 2

Explanation: The document indicates significant financial distress, a default on loan obligations, and a pending bankruptcy filing, all of which are very negative for investors.

Positives

• The forbearance agreement provides BIOLASE with a temporary reprieve from immediate loan enforcement actions.
• The $2.5 million bridge loan will help cover operating expenses during the forbearance period.
• The agreement allows BIOLASE to pursue a structured sale of assets through Chapter 11 bankruptcy.

Negatives

• BIOLASE is in default on its credit agreement, indicating significant financial distress.
• The company is preparing to file for Chapter 11 bankruptcy, which is a negative outcome for shareholders.
• The company's stock has been delisted from Nasdaq, reducing its visibility and accessibility to investors.
• The company is subject to strict budget controls and cannot pay executive bonuses without lender consent.

Risks

• Failure to meet the milestones outlined in the forbearance agreement could lead to immediate enforcement actions by lenders.
• The bankruptcy process is subject to court approval and could be delayed or altered.
• The sale of assets may not generate sufficient funds to repay all debts.
• The company's financial situation is precarious, and there is a risk of further deterioration.
• The company is restricted from making expenditures on its business to consumer laser product line.

Future Outlook

BIOLASE is preparing to file for Chapter 11 bankruptcy to facilitate the sale of its assets. The company's future depends on the success of this sale process and the terms of the bankruptcy court's approval.

Management Comments

• The document does not contain any direct quotes from management, but it does outline the actions taken by the company to address its financial difficulties.

Industry Context

The dental laser industry is competitive, and BIOLASE's financial struggles highlight the challenges faced by companies in this sector. The company's move to sell assets through bankruptcy suggests that it has been unable to compete effectively or manage its debt obligations.

Comparison to Industry Standards

• It is difficult to make a direct comparison to industry standards without more specific financial data for BIOLASE and its competitors.
• However, the need for a forbearance agreement and Chapter 11 bankruptcy suggests that BIOLASE is underperforming compared to its peers.
• Companies like Dentsply Sirona and Align Technology are larger and more established players in the dental technology market, and they are not facing similar financial difficulties.
• The delisting from Nasdaq is a significant negative indicator, as most successful companies in this sector maintain a listing on major exchanges.

Legal Proceedings

• The company is preparing to file for Chapter 11 bankruptcy in the United States Bankruptcy Court for the District of Delaware.

Stakeholder Impact

• Shareholders are likely to experience significant losses due to the bankruptcy filing and delisting.
• Employees may face uncertainty regarding their jobs during the restructuring process.
• Creditors are at risk of not being fully repaid.
• Customers may experience disruptions in service or product availability.
• Suppliers may face delays or non-payment of outstanding invoices.

Next Steps

• BIOLASE must execute a purchase and sale agreement with a stalking horse bidder by September 30, 2024.
• The company must file for Chapter 11 bankruptcy by October 1, 2024.
• The company must seek approval for the sale process from the bankruptcy court.
• The company must secure a DIP loan to fund operations during the bankruptcy process.
• The company must close the sale of assets by November 15, 2024.

Key Dates

Keywords

forbearance agreement, bankruptcy, Chapter 11, loan default, delisting, asset sale, bridge loan, restructuring, OTCQB, SWK Funding LLC